

APR 01 2004

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Addressed to:  Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	<i>Applicant(s):</i> Jerussi et al.	<i>Confirmation No.:</i> 2834
	<i>Serial No.:</i> 10/663,173	<i>Group Art Unit:</i> 1614
	<i>Filed:</i> 09/16/2003	<i>Examiner:</i> To Be Assigned
	<b>Title:</b> TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE AND ITS FORMAMIDE	

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Information Disclosure Statement is

submitted together with the application being filed herein; or  
 is submitted for the first time; or  
 submitted as a Supplemental Information Disclosure Statement in addition to an Information Disclosure Statement filed together with the application on September 16, 2003,

and such submission is being made:

under 37 CFR 1.97(b), within three months of filing national application or date of entry of international application, or before mailing date of first office action on the merits, whichever occurs last; or  
 under 37 CFR 1.97(c) together with either a:  
 Statement under 37 CFR 1.97(e), or  
 a \$180.00 fee under 37 CFR 1.17(p), after the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first; or  
 under 37 CFR 1.97(d), filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee, together with a:  
 Statement under 37 CFR 1.97(e), and  
 a \$180.00 fee set forth in 37 CFR 1.17(p);

and, furthermore, it is being submitted to disclose results of an International Search Report received in a related PCT application, Serial No. PCT/US03/29110 filed on September 16, 2003.

Applicant(s) submit herewith Information Disclosure Citation form listing patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56, together with any required copies of references.


It is requested that the information disclosed herein be made of record in this application.

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450


Date of Deposit: March 29, 2004

  
EDWARD TIMMER

*Respectfully submitted,*

  
EDWARD TIMMER  
Attorney for Applicant(s)  
Registration No. 46,248  
Dated: March 29, 2004

HESLIN ROTHENBERG FARLEY & MESITI, P.C.  
5 Columbia Circle  
Albany, New York 12203  
Telephone: (518) 452-5600  
Facsimile: (518) 452-5579



SUPPLEMENTAL INFORMATION DISCLOSURE CITATION	Docket No.: 0701.196A	Serial No.: 10/663,173
	Inventors: Jerussi et al.	Examiner: To Be Assigned
	Filing Date: 09/16/2003	GAU: 1614

#### UNITED STATES PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

#### FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Int'l Class	Int'l Subclass	Translation	
							Yes	No

#### OTHER DOCUMENTS

(Including Author, Title, Date Pertinent Pages, Etc.)

CG	Deninno, Michael P.; Eller, C; Etienne J B: "The preparation and intra-and intermolecular addition reactions of acyclic n-acylimines: Application to the synthesis of (+) sertraline" JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 66, 2001, pages 6988-6993, XP002902612, ISSN: 0022-3263; scheme 4, page 6992.
CH	Fuller, Ray W. et al.: PROG. NEURO-PSYCHOPHARMACOL. BIOL. PSYCHIAT., vol. 19, 1995, pages 135-149, XP002270139 abstract.
CI	Harrison, Ian T., Harrison Shuyen: "Compendium of Organic Synthetic Methods" 1971, John Wiley & Sons, New York, XP002270140, page 258-259.

EXAMINER:	Date Considered:
-----------	------------------

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.